Bio-Techne Corporation (TECH:NASDAQ) closed at $72.55 on October 23, 2026, down 0.10% on the day. The stock trades 0.2% below its 52-week high of $72.69 and 67.9% above its 52-week low of $43.20. Over the past year, it gained 10.1%. Bio-Techne Corporation is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 23, 2025, TECH closed higher on 125 days (50%). Its best day was June 25, 2026 (+20.07%) and its worst was May 6, 2026 (-16.35%). The stock moved 10% or more in a single session 3 times. It opened at least 5% above the previous day's high 1 time.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company operates through three segments: Biotechnology, Clinical Controls, and Protein Platforms. The Biotechnology segment provides proteins, such as cytokines, growth factors, and enzymes; polyclonal antibodies in goats, sheep, and rabbits, as well as monoclonal antibodies; microtiter-plate based kits, immunoassays based on encoded bead technology and planar spotted surfaces, and microfluidic-based immunoassays to quantify the level of a specific protein in biological fluids; and erythropoietin, transferrin receptor, and Beta2-microglobulin immunoassays for use as in vitro diagnostic devices. This segment also offers fluorochrome labeled antibodies and kits to determine the immuno-phenotypic properties of cells from various tissues; and natural or synthetic chemical compounds for use as agonists, antagonists, and/or inhibitors of various biological functions. The Clinical Controls segment provides hematology controls and calibrators for hematology clinical instruments; clinical controls for blood glucose and...
Find more stocks like TECH with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.